Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1

By: StockStory

May 08, 2025 at 18:17 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

PACB Cover Image

Genomics company Pacific Biosciences of California (NASDAQ: PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% above analysts’ consensus estimates.

Is now the time to buy PacBio? Find out by accessing our full research report, it’s free.

PacBio (PACB) Q1 CY2025 Highlights:

Revenue: $37.15 million vs analyst estimates of $35.3 million (4.3% year-on-year decline, 5.2% beat)
Adjusted EPS: -$0.15 vs analyst estimates of -$0.19 (20.5% beat)
Operating Margin: -1,155%, down from -210% in the same quarter last year
Market Capitalization: $339 million

“We are off to a solid start to the year, highlighted by a full quarter of shipments of the Vega platform, record consumables revenue and improved non-GAAP gross margin,” said Christian Henry, President and Chief Executive Officer.

Company Overview

Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ: PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.

Sales Growth

Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, PacBio’s sales grew at a decent 11.1% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. PacBio’s recent performance shows its demand has slowed as its annualized revenue growth of 6.6% over the last two years was below its five-year trend. PacBio Year-On-Year Revenue Growth

This quarter, PacBio’s revenue fell by 4.3% year on year to $37.15 million but beat Wall Street’s estimates by 5.2%.

Looking ahead, sell-side analysts expect revenue to grow 10.2% over the next 12 months, an improvement versus the last two years. This projection is noteworthy and implies its newer products and services will fuel better top-line performance.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Operating Margin

PacBio’s high expenses have contributed to an average operating margin of negative 256% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It’s hard to trust that the business can endure a full cycle.

Analyzing the trend in its profitability, PacBio’s operating margin decreased significantly over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 300 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

PacBio Trailing 12-Month Operating Margin (GAAP)

PacBio’s operating margin was negative 1,155% this quarter. The company's consistent lack of profits raise a flag.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

PacBio’s earnings losses deepened over the last five years as its EPS dropped 1.8% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, PacBio’s low margin of safety could leave its stock price susceptible to large downswings.

In Q1, PacBio reported EPS at negative $0.15, up from negative $0.26 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects PacBio to improve its earnings losses. Analysts forecast its full-year EPS of negative $0.70 will advance to negative $0.69.

Key Takeaways from PacBio’s Q1 Results

We were impressed by how significantly PacBio blew past analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this was a good print with some key areas of upside. Investors were likely hoping for more, and shares traded down 2.5% to $1.16 immediately following the results.

So do we think PacBio is an attractive buy at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it’s free.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	244.19	-1.03 (-0.42%)
AAPL	290.55	-10.99 (-3.64%)
AMD	475.50	-14.82 (-3.02%)
BAC	54.42	+0.79 (1.47%)
GOOG	362.29	+1.12 (0.31%)
META	584.59	-0.80 (-0.14%)
MSFT	403.41	-8.33 (-2.02%)
NVDA	208.19	-0.45 (-0.22%)
ORCL	205.81	-6.01 (-2.84%)
TSLA	396.68	-12.27 (-3.00%)